US Government secures additional doses of Novavax
As the country continues its fight against the COVID-19 pandemic, the government has taken a significant step to secure additional doses of the Novavax COVID-19 vaccine. The federal government has recently adjusted its existing agreement with Novavax to secure extra supplies of the COVID-19 vaccine, NVX-CoV2373. Within the framework of this amended agreement, Novavax has committed to delivering an additional 1.5 million doses of its COVID-19 vaccine and ensures continued public access to it. The need for extra doses The decision to purchase more doses of the Novavax COVID-19 vaccine reflects the nation’s commitment to bolstering its supply. This move acknowledges the need to offer the American people a diverse COVID-19 vaccine portfolio. It underscores the importance of Novavax’s partnership with the U.S. government to ensure continuous access to a protein-based option as part of public health measures. About the Novavax COVID-19 vaccine The Novavax COVID-19 vaccine, or NVX-CoV2373, is a protein subunit vaccine designed to stimulate an immune response against the SARS-CoV-2 virus, which causes COVID-19. It differs from the mRNA and viral vector vaccines as it uses a different approach. Novavax’s vaccine uses a harmless piece of the coronavirus’s spike protein to trigger an immune response without using live or weakened virus components.
